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Purpose: To investigate the candidacidal activity of a novel compound CF66I and attempt to elucidate 
its mode of action. 
Methods: Minimal inhibition concentrations (MIC) and minimal fungicidal concentrations (MFC) of CF66I 
for Candida albicans were determined using serial broth dilution method. Colony count assay, K
+
 
release, propidium iodide (PI) uptake and electron microscopy were used to determine the manner in 
which CF66I exerts its candidacidal effects. 
Results: MIC and MFC of CF66I were determined to be 5.0 - 7.0 µg/ml and 14.0 - 18.0 µg/ml. It showed 
strong candidacidal activity over a wide pH range (4.0-7.4). The compound killed C. albicans within 30 s. 
It preferentially bound to the surface of C. albicans via a specific interaction with β-1,6-glucan, one of 
fungal cell wall components, and then affected the normal structure of fungal cell wall and induced cell 
wall thickening, which was confirmed by transmission electron microscopy (TEM) CF66I also exerted its 
candidacidal activity against cell membrane, eventually induced K
+
 release from C. albicans and PI 
uptake. Membrane-attacking ability was also found via electron microscopy. 
Conclusion: These results suggest that CF66I exerted its candidacidal activity on multiple target sites 
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INTRODUCTION 
 
As an important opportunistic fungus, 
Candida albicans causes a wide range of 
infections ranging from surface diseases of 
the skin and mucosae to deep tissue 
infections in individuals [1,2]. Some drugs for 
the treatment of Candida infections have 
been developed, such as polyene and 
azoles, which are regarded as the most 
effective for controlling serious fungal 
infections so far [3]. However, extensive use 
of the currently available antifungal drugs 
leads to a variety of associated problems with 
human health due to their significant side 
effects, and the emergence of large amounts 
of drug-resistant strains worldwide [4]. 
Therefore, the development of new antifungal 
agents with increased clinical usefulness in 
terms of efficacy and/or safety is needed. 
 
During the search for antagonists of plant 
pathogenic fungi, a novel antifungal 
compound named CF66I and produced by 
Burkholderia cepacia was obtained. 
Preliminary structural analyses confirmed that 
CF66I was a complicated compound having 
amide bonds, α-methyl fatty acid, bromine, 
and some structural units such as CH2CH2O 
[5]. Previous studies reported its broad-
spectrum activity against plant pathogenic 
fungi [6]. By fluorescent staining and 
transmission electron microscopy, it was 
observed that high doses of CF66I were 
fungicidal with membrane-attacking ability, 
whereas low doses were fungistatic by 
interfering with the cell metabolic pathways 
[7, 8]. Therefore, it was considered to be a 
promising candidate for the development of a 
novel antibiotic. However, the mechanism 
underlying the aforementioned activities was 
not clearly understood. In this study, 
candidacidal activity of CF66I has been 
investigated: we also attempted to determine 
the manner in which CF66I exerts its 





Antifungal substances  
 
The compound, CF66I, was prepared by 
three-step gel chromatography as previously 
described [6], and then held at 4 °C for use. 
 
Organism and culture media 
 
C. albicans (CGMCC 2.538) was obtained 
from China General Microbiological Culture 
Collection Center. It was subcultured twice on 
yeast peptone dextrose (YPD) agar plate 
(yeast extract 1 %, peptone 1 %, dextrose 2 
% and agar 2 %) at 28 °C prior to testing. 
YPD broth used in this study contains yeast 
extract 1 %, peptone 1 % and dextrose 2 %.  
 
MIC and MFC assay 
 
MIC and MFC were determined for CF66I 
against C. albicans using serial broth dilution 
method. YPD broth (100 µl) containing 
different concentrations of CF66I (0 to 30.0 
µg/ml) was inoculated with 10 µl of fungal 
suspension (10
7
 cfu/ml), and then the mixture 
was incubated in a 96-well plate at 28 °C for 
48 h. The MIC end-point criterion was defined 
as the lowest compound concentration 
showing no visible growth after 24-h 
incubation. To obtain the MFC values, 10 µl 
of the test samples was taken from every well 
and spread on YPD plates, then cultivated at 
28 °C for 48 h. MFC was defined as the 
lowest compound concentration at which no 
visible growth was observed. Triplicate 
determinations were performed. 
 
Colony count assay 
 
Aliquots (2 ml) of C. albicans (10
7
 cfu/ml) in 
YPD broth was incubated with different 
concentrations of CF66I at 28 °C in a shaker 
incubator, and then 100-µl aliquots were 
removed at predetermined time intervals. 
Each of the aliquots directly or after dilution 
was spread on YPD agar plates. The 
resultant colonies were then counted, after 
incubation for 48 h at 28 °C.  
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Effect of pH on candidacidal activity of 
CF66I 
 
To evaluate the influence of pH on 
candidacidal activity of CF66I, the pH of YPD 
broth containing CF66I (16 µg/ml) was 
adjusted to 4.0, 5.0, 5.11, 6.0, 7.0 or 7.4, with 
1M NaOH or 1M HCl. Each medium with 
different pHs was inoculated with 1% of the 
fungal suspensions. The cultivation was 
performed with shaking at 28 ºC for 1 min, 
while CF66I-free solutions with different pH 
values were used as the controls. Fungal 
growth was measured by counting the 
colonies on YPD agar plates. At each pH, 
CF66I activity was calculated as {1-(cfu of 
CF66I-treated sample/cfu of the control)} × 







The leakage of K
+
 from C. albicans was used 
to monitor the cell membrane damage 
inflicted by CF66I. K
+
 content was examined 
with a flame spectrometer (Hitach Z-2000).
 
In 
brief, C. albicans cells were cultured in YPD 
broth at 28 ºC. After 18 h of incubation, cells 
were harvested by centrifugation, washed 
twice with distilled water, and then 
resuspended to 10
7 
cfu/ml. One millimeter of 
the cell suspensions were incubated with 
different concentrations of CF66I at 28 ºC. At 
predetermined intervals, samples (0.1 ml) 
were taken, centrifuged to remove the cells, 
and the resulting filtrates were assayed for K
+ 
content. Total cellular K
+
 was determined 
after the cell suspension was incubated for 
30 min in a boiling water bath. Triplicate 
determinations were performed, and the 
mean values were utilized in the construction 
of a graph. The percent K
+
 release was then 
calculated, according to the following 
equation: K
+ 














The integrity of cell membrane after CF66I 
treatment was examined by was determined 
by FACScan analysis, via nuclear staining 
with propidium iodide (PI; Sigma). C. albicans 
cells were harvested and washed twice with 
distilled water. The washed cells (10
7 
cells) 
were incubated with different concentrations 
of CF66I at 28 ºC for 10 min, and 
subsequently stained with PI (100 µg/ml) for 
30 min at 4 ºC. After this operation, the 
unbound dye was removed by washing with 
distilled water. Flow cytometry analysis was 





For SEM, C. albicans cells were harvested by 
centrifugation and washed twice with PBS, 
then fixed with 2% glutaraldehyde in 0.1M 
PBS (pH 7.4) at 4 ºC for 1 h. After fixation, 
the samples were centrifuged at 4000 rpm 
and rinsed three times for 20 min each with 
sodium cacodylate buffer. The samples were 
then dehydrated through a graded ethanol 
series and freeze-dried for 8 h, then coated 
with a light coat of gold palladium. 
Observations were carried out with an S-
3800 scanning electron microscope (Hitachi, 
Japan).  
 
For TEM, cells fixed with 2% glutaraldehyde 
solution as described above, were postfixed 
with 1% OsO4 solution for 20 h at 4 ºC. 
Dehydration was carried out in a degraded 
series of ethanol before embedding in resin. 
Ultra-thin sections were cut with a Reichert-
Nissei Ultracut N, stained with uranyl acetate, 
followed by lead citrate and then examined 
with a JEM-2000EX electron microscope 
(Japan) using an accelerating voltage of 120 
kV.  
 
Assay for binding of CF66I to the 
component of fungal cell wall 
 
Binding property of CF66I to the surface of C. 
albicans was determined by assessing the 
effect of fungal cell wall components on the 
anti-Candida activity of CF66I in 
ultrasensitive radial diffusion assay as 
described previously [9]. 50 µl of 1 mg/ml 
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CF66I solution was added to 50 µl of 
laminarin (β-1,3-glucan polymer, Sigma), 
pustulan (β-1,6-glucan polymer, Sigma), 
chitin (N-acetylglucosamine polymer, Sigma) 
or mannan (mannose polymer, Sigma), each 
of which was serially diluted two-fold to 
concentrations ranging from 0.5 to 8.0 mg/ml, 
and the mixtures incubated at 30 ºC for 2 h. 
50 µl samples were loaded into 6-mm 
diameter wells that had been pre-punched on 
YPD agar plates in which the washed C. 
albicans (10
7
 cfu/ml) was trapped. After the 
plates were incubated overnight at 28ºC, the 
diameters of clearing zones indicating 
antifungal activity were plotted against 




The results are presented as the means of 
three individual experiments. Statistical 
significance was determined by one-way 
analysis of variance (ANOVA) and Student’s 
t-test using OriginPro 8.0 software 
(OriginLab). P<0.05 was used in determining 




MIC and MFC assay 
 
CF66I exhibited excellent fungistatic and 
fungicidal activities against C. albicans. By 
the serial dilution method, an MIC of CF66I 
for C. albicans was determined to be 6.0 
µg/ml, while the MFC value was 18.0 µg/ml.  
 
Influence of pH on CF66I activity  
 
CF66I possessed excellent candidacidal 
activity over a wide pH range of 4.0 to 7.4 
(Fig 1). Greatest fungicidal effect against C. 
albicans was observed at pH values ranging 
from 6.0 to 7.4 (> 90 %), which was close to 
the physiological pH of human serum. While 
at pH lower than 6.0, CF66I activity 
decreased by about 75 %.  
 
Figure 1: Influence of pH on candidacidal activity 
of CF66I 
 
Effect of CF66I on the membrane integrity 
of C. albicans  
 
Colony count assay showed that candidacidal 
activity of CF66I was dose-dependent. CF66I 
concentration of 16.0 µg/ml caused a 
significant reduction (approx 90 %) in cell 
viability. Short time course analysis (5 min) 
revealed that the minimal number of viable 
cells was achieved after 30 s of incubation 
with CF66I, and then reached a plateau 
thereafter (Fig 2a), thereby illustrating the 
marked rapidity with which CF66I killed the C. 
albicans cells; its candidacidal activity was 
completed within 30 s.  
 
Fig 2b showed the release of K
+
 from C. 
albicans treated with CF66I for the 
predetermined time. About 95.2 % of the total 
intracellular K
+
 was released after 5-min 
incubation with 16.0 µg/ml of CF66I, and the 
percentage of K
+
 efflux remained constant 
during further incubation. The time course 
associated with K
+
 release from the C. 
albicans exhibited a pattern consistent with 
the results obtained from the colony count 
assay for the candidacidal activity of CF66I. 
Therefore, we concluded that CF66I induced 
an immediate and massive efflux of K
+
 from 
C. albicans. Fig 2c shows the results of the 
intracellular PI measurements. The C. 
albicans cells were labeled fluorescently after 
5-min of incubation with CF66I, thereby 
indicating that CF66I induced the uptake of PI 
into the cells. 
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Figure 2: Effect of CF66I on the cell membrane of 
C. albicans (a) Colony count assay for the 
candidacidal activity of CF66I (b) CF66I-induced 
K
+
 release from C. albicans. (c) Flow cytometric 
analysis. C. albicans cells were treated without 
(dark line) and with CF66I (green line, 16 µg/ml; 
red line, 8 µg/ml), and then stained with PI. 
Cellular fluorescence was examined by FACScan 
flow cytometry. The increase in fluorescence 
intensity represents the PI uptake to the cells 
( ﹦ ﹦○ control; ▼ 8 µg/ml; ﹦▲ 12 µg/ml; ﹦□ 16 
µg/ml) 
Electron microscopic studies 
 
Morphological changes of C. albicans 
induced by CF66I were shown in Figs 3 and 
4. Control cells exhibited an ovoid shape with 
smooth surfaces. The average diameters 
were 1 to 3 µm. Normal buds and bud scars 
were observed (Fig 3a). TEM images 
revealed that the control cells presented a 
typical multilayered cell wall with an outer 
electron-dense layer, and the thickness was 
about 100 nm. Typical features of organelles, 
i.e., nucleus, mitochondria and vacuoles are 




Figure 3: Scanning electron microscopy. (a) 
Control cells. All cells lie apart, showing smooth 
surfaces and normal bud scars; (b, c, d) Cells 
exposure to CF66I (16 µg/ml) for 30 min. Note the 
obvious increased volume of CF66I-treated cells 
and the formation of interconnected cells. Cell 
surfaces were wrinkled, and some pores and 
cracks (d, arrows) were observed on the cell wall. 
In addition, randomly distributed bud scars were 
visible (c, arrows). 
 
However, profound alterations in cell 
morphology of C. albicans were observed 
after exposure to CF66I, including surface 
roughening and disruption (Fig 3b, 3c and 
3d). In addition, this compound caused the 
clusters of interconnected cells with buds and 
bud scars irregularly located on the cell 
surface. Abnormal cell division observed in 
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morphologically changed cells demonstrated 
inhibition of normal development of buds or 
daughter cells and their separation from 
parent cells. Meanwhile, SEM images 
showed swollen and aberrantly deformed 
cells of C. albicans, which were at least three 
times larger than control (Fig 3b and 3c).  
 
Ultrastructural modifications of CF66I-treated 
C. albicans were observed via TEM. 16.0 
µg/ml of CF66I induced the partial 
solubilization of cytoplasmic membrane and 
the prominent enlargement of nucleus (Fig 
4b); however, the cell volume did not change 
at this time. After incubation with CF66I for 30 
min, cells swollen obviously, and the dramatic 
disruptions of cell membrane were observed. 
Whereas some CF66I-treated cells remain 
intact like the control, the cell interior was 
completely necrotic, and only several fat 




Figure 4: Ultrastuctural modifications of C. 
albicans examined by TEM after exposure to 
CF66I. (a) Control cell. Cell wall (CW), cell 
membrane (CM), mitochondria (M), nucleus (N) 
and vacuoles (Vac) were clearly seen (×12000). 
(b) Cells exposure to 16 µg/ml of CF66I for 10 min. 
Note the loosening and thickening of cell walls, 
damage of the cell membrane (arrows) and the 
enlargement of nucleus. (c, d) Cells exposure to 
16 µg/ml of CF66I for 30 min. The cells swelled, 
whereas the cell remained intact, cell interior was 
completely necrotic and became empty. Only 
some fat deposits (F) were observed.  
The cytoplasm leakage probably related with 
the cracks and pores on the cell wall (Fig 3d).  
However, of particular interest were the 
observations of fungal cell wall thickening 
with its thickness increasing to about 500 nm 
(Fig 4b, 4c and 4d).  
 
Specific binding of CF66I to the 




Figure 5: Specific binding of CF66I to pustulan. 
Radial diffusion assay was performed by mixing 
various amounts of laminarin (■), pustulan (●), 
chitin (○) or mannan (▲) with 25 µg of CF66I in a 
final volume of 50 µl. The mixtures of CF66I with 
each polysaccharide were introduced into the 
wells of YPD agar plates pre-seeded with C. 
albicans suspensions (10
7
 cfu/ml). The anti-
Candida activities of CF66I in the mixture were 
graphed against concentrations of polysa-
ccharides.  
 
In order to investigate if CF66I specifically 
binds to fungal cell surface, the effects of 
main cell wall polysaccharides on the anti-
Candida activity of this compound were 
examined (Fig 5). The constant amount of 
CF66I was incubated with different 
concentrations of laminarin, mannan, chitin or 
pustulan, and then the mixture was tested for 
anti-Candida activity in agar diffusion assay. 
As a result, its activity was significantly 
reduced as the amount of pustulan increased 
in the mixture. By contrast, the other 
polysaccharides affected the anti-Candida 
activity of CF66I. These results indicated that 
pustulan prevented the compound from 
interacting with the cell surface of C. 
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albicans, resulting in the abrogation the 
CF66I-induced antifungal activity in a dose-
dependent manner. Therefore, it was 
concluded that CF66I bound to C. albicans 
cells via a specific interaction with β-1,6-




Despite the existence of many currently 
available antifungal drugs, the increasing 
prevalence of life-threatening fungal diseases 
means that it is necessary to develop new, 
safer and more effective antifungal agents. In 
this paper, the compound CF66I exhibited 
excellent candidacidal activity. MIC and MFC 
values indicated that it could be regarded as 
a most promising candidate for the 
development of novel therapeutic agents for 
Candida infections. Moreover, it kept a good 
biological control performance over a wide 
pH range of 4.0 to 7.4. Especially at pH 
values near to the human physiological 
environment (6.0-7.4), the compound could 
exert its optimal candidacidal effect. 
 
In order to elucidate the mechanisms 
underlying candidacidal activity, we 
attempted to determine the manner in which 
CF66I carried out the destruction of C. 
albicans. Colony count assay indicated CF66I 
could kill the C. albicans cells within 30 s. 
Many reports have been published about the 
rapid killing process of antifungals, for 
instance, some natural peptides could exert 
their antibacterial or fungicidal effects within a 
few minutes, and this effect was most 
plausible attributed to the action of these 
compounds on the cytoplasmic membranes 
[9, 10]. Accordingly, the results of our study 
led us to hypothesize that CF66I might act on 
the cell membrane of C. albicans, thus 
inducing cell lysis. Consistent with our 
hypothesis, CF66I treatment induced the 
release of intracellular K
+
 (Fig 2b) and an 
obvious uptake of PI into the cells (Fig 2c). 
Consequently, the rapid candidacidal manner 
of CF66I was considered to act primarily on 
the cell membrane of C. albicans. 
 
Cell wall is a unique organelle to fungi, not 
found in mammal cells, which has been 
regarded as an ideal target for the search of 
novel antifungal agents [11]. SEM and TEM 
images revealed the prominent alterations on 
the cell wall of C. albicans induced by CF66I 
(Fig. 3 and Fig. 4). Thickening of the fungal 
cell wall and an obvious increase in the 
thickness was observed (more than three 
times than control). However, no obvious 
alterations were observed in the composition 
of the fungal cell wall polysaccharides (data 
not shown). Thus, the ultrastructural changes 
of cell wall was not similar to some inhibitors 
of glucan synthesis, such as cilofungin 
(LY121019) and papulacandin B, which were 
reported to have secondary effects on other 
components of intact cells including an 
increase in the chitin content of the cell wall, 
and this could result in thickened fungal cell 
walls [3]. Recent evidences indicated that 
another mechanism similar to benanomicins 
and pradimicins may be used to explain the 
action mode of CF66I against the fungal cell 
wall. These two drugs killed the fungal cells 
by damaging the fungal cell wall structure by 
forming an insoluble complex with 
polysaccharide (mannan) [12,13]. However, 
when CF66I was mixed with cell wall 
polysaccharides, no insoluble complex was 
observed, but specific binding of CF66I to β-
1,6-glucan was observed and its antifungal 
activity changed, which maybe the reason of 
CF66I-inducing changes on fungal cell wall.  
 
Electron microscopic observations also 
clearly confirmed the candidacidal action 
exerted by CF66I. Profound morphological 
alterations were observed, such as cells 
swollen and distortion, which were most 
probably due to a change in cell permeability. 
These results were in agreement with earlier 
ultrastructural observations, indicating that 
the first changes are localized at the cell 
membrane or cell wall before any alteration 
can be detected in the cell interior [14]. 
Meanwhile, an obvious increase in buds and 
bud scars at several regions of the cell 
surface (Fig 3c) implied that the compound 
CF66I probably affected the normal division 
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process of C. albicans; however, that such 
attempts did not result in a great number of 
viable cells was evidenced by colony count 
assay. Moreover, the inability of cells to 
separate, resulting in the formation of 
numerous clusters of interconnected cells, 




Results from the present study indicated that 
the novel compound CF66I possesses 
excellent and rapid candidacidal activity, and 
its action mode can be interpreted in multiple 
ways. During the interaction of CF66I with C. 
albicans, it preferentially bound to β-1,6-
glucan, and then exerted its antifungal activity 
to the cell membrane, eventually inducing the 
profound morphological changes and cell 
death. Studies on this compound maybe 
useful for us to develop a new class of 
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